· New TECVAYLI® (teclistamab-cqyv) + TALVEY® (talquetamab-tgvs) Phase 3 data demonstrate reduced risk of disease progression in relapsed or refractory multiple myeloma as early as second line · First results from ramantamig, an investigational trispecific antibody, with DARZALEX® (daratumumab) and lenalidomide in transplant-eligible newly diagnosed multiple myeloma showed deep and durable responses across multiple lines of therapy · Positive Phase 2 results for bleximenib in relapsed or refractory acute myeloid leukemia with KMT2A rearrangements or NPM1 mutations, supported by two Breakthrough Therapy Designations · First data for a novel, potentially disease-modifying CALRmut × CD3 T-cell engaging antibody targeting a disease-defining driver mutation in essential thrombocythemia, supported by Breakthrough Therapy and Priority Medicines designations